ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study | Prof Felix Mahfoud

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this short late-breaking interview, Prof Felix Mahfoud (Saarland University Hospital, Hamburg, DE) discusses the 3-year efficacy outcomes of the SPYRAL HTN-ON MED Pilot Study (NCT02439775).
The global clinical study, presented at ACC.22, tested the long-term effect of renal denervation (Symplicity Spyral™ multi-electrode renal denervation system, Medtronic Vascular) on blood pressure reduction in patients on antihypertension medications.

Discussion Points:
-Importance of the SPYRAL HTN-ON MED Pilot Study
-Design, Patient Cohort and Endpoints
-Key Findings
-Influence on Guideline Recommendations
-Remaining Questions & What is Left for Renal Denervation
-Take-home Messages

Recorded on-site at ACC.22, Washington DC.
Interviewer: Mirjam Boros

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.